Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics managing director buys more shares on-market

A number of board members have purchased shares in the company in 2019 to date.
three empty board seats
The shares were purchased at an average price of 15.5 cents each

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills has purchased 65,000 shares in the company via on-market trades.

The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

cannabis plant
May 05 2019
The cannabis company invests in income-producing property and provides financing solutions and capital investment to service the blossoming cannabis industry
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
muffins and cannabis
November 29 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use